SCHEMBL25320313

SCHEMBL25320313

OC1(c2nc3cc(Cl)ccc3s2)CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
DRD2 P14416 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
IDO1 P14902 1/20 0.42
PPARA Q07869 6/20 0.40
HDAC6 Q9UBN7 1/20 0.40
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37
HTR3C Q8WXA8 1/20 0.37
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24365338 0.83 NPC1 (0.51) NPC1RAB9ADRD2SMN1; SMN2NPSR1
SCHEMBL30470829 0.83 NPC1 (0.51) NPC1RAB9ADRD2SMN1; SMN2NPSR1
SCHEMBL25322228 0.81 SMN1; SMN2 (0.43) NPC1RAB9ADRD2SMN1; SMN2NPSR1
SCHEMBL24367034 0.80 NPC1 (0.48) NPC1RAB9ADRD2SMN1; SMN2NPSR1
SCHEMBL30469983 0.80 NPC1 (0.48) NPC1RAB9ADRD2SMN1; SMN2NPSR1
SCHEMBL30034871 0.75 NPC1 (0.48) NPC1RAB9ASMN1; SMN2PPARAGAA
SCHEMBL29690499 0.75 NPC1 (0.48) NPC1RAB9ASMN1; SMN2PPARAGAA
SCHEMBL30036653 0.74 NPC1 (0.50) NPC1RAB9ASMN1; SMN2PPARAGAA
SCHEMBL24367036 0.72 PPARA (0.44) NPC1RAB9APPARAMEN1KMT2A
SCHEMBL30610130 0.70 LOXL2 (0.49) NPC1RAB9ADRD2SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN NPC1 383/4885RAB9A 324/4885DRD2 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.